Medical Device Deals Update, May 2012
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
You may also be interested in...
The FDA commissioner also does not want the agency setting goals for rare disease treatment development.
Aggressive staffing goals for FDA’s gene and cell therapy review group might not be fully achieved – but the head of CBER believes the new organization is on track to deliver on his high expectations going forward.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.